Blood:采用HSCT治疗的恶性血液病患儿的长期预后

2020-04-06 MedSci原创 MedSci原创

儿童造血干细胞移植(HSCT)幸存者的患者报告的预后尚无统计数据。本研究提供了采用HSCT治疗的恶性血液病患儿的长期预后信息。

儿童造血干细胞移植(HSCT)幸存者的患者报告的预后尚无统计数据。

在本研究中,Hsiu-Ju Yen等人对比了儿童期接受HSCT治疗的血液系统恶性肿瘤成年幸存者与接受常规治疗和非癌症对照组的症状患病率、健康相关生活质量(HRQOL)和危险因素。

来自St. Jude终生队列研究的儿童血液系统恶性肿瘤的存活者(HSCT组:112位[70%异体,30%自体];常规治疗组:1106位)和非癌症对照(242位)完成了评估10个症状域和SF-36 HRQOL总评分的调查表。并通过临床评估验证了慢性健康状况(CHCs)。

多变量逻辑回归分析显示,与非癌症对照组相比,HSCT幸存者在感觉、运动、肺和记忆方面的症状患病率明显更高,体能HRQOL评分更低。HSCT和常规治疗的幸存者所有症状的患病率和HRQOL评分相似;但HSCT幸存者的特定症状的累积患病率明显更高如戴眼镜时出现复视、干眼和视物困难。除了疼痛和焦虑外,器官特异性CHCs的发生与儿童癌症成年幸存者中所有症状的高患病率显著相关。

本研究发现,HSCT和常规治疗的血液系统恶性肿瘤幸存者的患者报告的预后的受损程度相当,但与非癌症对照相比,两组患者报告的预后均较差。在所有儿科血液系统恶性肿瘤的幸存者中,不论采用传统疗法还是造血干细胞移植,患者报告的不良预后均与CHCs的存在相关。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1658610, encodeId=c6211658610c6, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Tue Jun 09 01:33:38 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645627, encodeId=3e20164562eeb, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Tue Nov 03 20:33:38 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515149, encodeId=83f3151514992, content=<a href='/topic/show?id=7acc52955b3' target=_blank style='color:#2F92EE;'>#恶性血液病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52955, encryptionId=7acc52955b3, topicName=恶性血液病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4dc10724136, createdName=ms9608593228839890, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578431, encodeId=755715e8431b9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9144, encryptionId=cabf914424, topicName=HSCT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0df016405434, createdName=ms691033630344116, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
    2020-06-09 sjq035
  2. [GetPortalCommentsPageByObjectIdResponse(id=1658610, encodeId=c6211658610c6, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Tue Jun 09 01:33:38 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645627, encodeId=3e20164562eeb, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Tue Nov 03 20:33:38 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515149, encodeId=83f3151514992, content=<a href='/topic/show?id=7acc52955b3' target=_blank style='color:#2F92EE;'>#恶性血液病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52955, encryptionId=7acc52955b3, topicName=恶性血液病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4dc10724136, createdName=ms9608593228839890, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578431, encodeId=755715e8431b9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9144, encryptionId=cabf914424, topicName=HSCT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0df016405434, createdName=ms691033630344116, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1658610, encodeId=c6211658610c6, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Tue Jun 09 01:33:38 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645627, encodeId=3e20164562eeb, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Tue Nov 03 20:33:38 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515149, encodeId=83f3151514992, content=<a href='/topic/show?id=7acc52955b3' target=_blank style='color:#2F92EE;'>#恶性血液病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52955, encryptionId=7acc52955b3, topicName=恶性血液病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4dc10724136, createdName=ms9608593228839890, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578431, encodeId=755715e8431b9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9144, encryptionId=cabf914424, topicName=HSCT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0df016405434, createdName=ms691033630344116, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1658610, encodeId=c6211658610c6, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Tue Jun 09 01:33:38 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645627, encodeId=3e20164562eeb, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Tue Nov 03 20:33:38 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515149, encodeId=83f3151514992, content=<a href='/topic/show?id=7acc52955b3' target=_blank style='color:#2F92EE;'>#恶性血液病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52955, encryptionId=7acc52955b3, topicName=恶性血液病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4dc10724136, createdName=ms9608593228839890, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578431, encodeId=755715e8431b9, content=<a href='/topic/show?id=cabf914424' target=_blank style='color:#2F92EE;'>#HSCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9144, encryptionId=cabf914424, topicName=HSCT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0df016405434, createdName=ms691033630344116, createdTime=Tue Apr 07 15:33:38 CST 2020, time=2020-04-07, status=1, ipAttribution=)]

相关资讯

《2017年意大利共识指南:血液系统恶性肿瘤以及接受造血干细胞移植患者HBV再激活的筛查、监测、预防和预防性治疗的建议》摘译

HBV再激活与血液系统恶性肿瘤/造血干细胞移植(HSCT)患者的高发病率和病死率相关,但关于这个问题的证据是有限的。本指南将提供该类患者的HBV筛查、监测、预防、治疗和疫苗接种的建议。综合意大利不同医学领域学会在同期刊物发表的关于血液病患者和接受HSCT患者HBV 感染的系统文献综述(至2016 年12 月31日)总结出该指南。

Int J Cardiol:血液系统恶性肿瘤患者急性冠状动脉综合征发病率、治疗和结局

由此可见,在这项针对患有活动性恶性血液病成人的大型现代研究中,ACS并不常见。

JCO:甲状腺癌放射性碘剂治疗后发生血液系统恶性肿瘤的风险

JCO近期发表了一篇文章,研究分化良好的甲状腺癌患者接受放射性碘剂治疗后出现继发性血液学恶性肿瘤的风险。

JCO:血液系统恶性肿瘤干细胞移植后认知功能

清髓性异体干细胞移植(HCT)后认知功能损害已得到公认,但是低强度异体或自体HCT后对认知功能的影响尚不清楚。JCO近期发表了一篇文章研究这一问题。

CLIN CANCER RES:Fenretinide静脉给药治疗复发或难治性血液系统恶性肿瘤

体外实验证实Fenretinide对淋巴细胞性白血病细胞系具有显著毒性作用,同时对成纤维细胞、外周血单核细胞以及髓系祖细胞的毒性很小,表明其在血液系统恶性肿瘤中具有治疗潜力。CLIN CANCER RES近期发表了一篇文章,研究Fenretinide静脉途径给药治疗血液系统恶性肿瘤的最大耐受剂量(MTD),剂量限制毒性(DLT)以及药代动力学。

Eur Respir J:实体肿瘤和血液系统恶性肿瘤患者结核病的风险!

考虑到癌症患者免疫抑制的时间有限,并且因为预期寿命的降低,会减少结核病的终生累积的风险,但儿童,而不是成人,似乎存在足够的风险水平来全面地筛查LTBI。